[1] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[2] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[3] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[4] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|
[5] |
SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong.
Thoughts on constructing vigilance system of Chinese medical device in the new era
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
|
[6] |
TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei.
Progress in the application of real-world data in post-market surveillance of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
|
[7] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[8] |
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana.
Introduction and inspiration of international medical device regulators forum patient registry guidelines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
|
[9] |
TAN Jing, LIU Chunrong, HUANG Shiyao, GAO Pei, WANG Yang, LI Chen, HE Yong, YUAN Hong, WANG Wen, LI Ling, XIONG Yiquan, REN Yan, YAO Minghong, ZHAO Yan, DONG Fang, SHEN Chuanyong, SUN Xin.
Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 13-17.
|
[10] |
LI Ling, LIU Yanmei, TAN Jing, WANG Wen, YAO Minghong, MA Yu, LUO Xiaochao, LIAO Xing, LIU Yan, SONG Haibo, WEN Zehuai, SUN Xin.
Developing a safety assessment model for Chinese patent medicines based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 18-22.
|
[11] |
ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling.
Methods for risk trend analysis of EU post-marketing surveillance for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82.
|
[12] |
MAO Zhenbin, LIU Shuyu.
Implications of Regulatory Science for the Construction of Medical Device Vigilance Systems
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 601-605.
|
[13] |
QIAO Rui, LIU Yuqiang, ZHUO Lin, MENG Ruogu, SUN Feng, ZHAN Siyan.
Application Scope of Real-World Data in Post-Marketing Drug Safety Monitoring and Evaluation for Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 620-623.
|
[14] |
LIU Yuqiang, QIAO Rui, ZHUO Lin, MENG Ruogu, SUN Feng, ZHAN Siyan.
Ethical Risks of Real-World Data in Post-Marketing Drug Safety Studies
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 628-631.
|
[15] |
ZHAO Yan, ZHAO Yifei△, ZHENG Lijia, DONG Fang.
Medical Device Vigilance Systems in European Union
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 566-569.
|